Which hormone is NOT given for palliative care of carcinoma of prostate: March 2013 (c, f)
**Question:** Which hormone is NOT given for palliative care of carcinoma of prostate: March 2013 (c, f)
**Core Concept:** Prostate-specific hormone therapy in palliative care for prostate cancer
Prostate cancer is a common malignancy in male patients, and hormonal therapy is often employed as a palliative measure to manage symptoms associated with the disease progression. The primary hormones involved in this context are:
1. Androgen Deprivation Therapy (ADT): This involves blocking the production of testosterone, the primary male sex hormone that promotes prostate cancer growth. Common ADT methods include:
- Gonadotropin-releasing hormone (GnRH) agonists: These stimulate the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the testes to produce testosterone. By blocking GnRH, these agents reduce testosterone levels.
- Gonadotropin-releasing hormone antagonists: These directly inhibit the secretion of LH and FSH, thus decreasing testosterone levels.
- Luteinizing hormone-releasing hormone (LHRH) agonists: These stimulate the pituitary gland to produce LH and FSH, which then stimulate the testes to produce testosterone. By blocking LHRH, these agents reduce testosterone levels.
- Luteinizing hormone-releasing hormone antagonists: These directly inhibit the secretion of LH and FSH, thus decreasing testosterone levels.
2. Estrogen antagonists (anti-estrogens): These are used when the cancer has spread to the bone and causes bone pain, as estrogen receptors are present in prostate cancer cells.
**Core Concept Explanation:** The rationale behind using hormonal therapy in prostate cancer is to suppress testosterone levels, as prostate cancer cells predominantly utilize androgens (testosterone and dihydrotestosterone) for growth and proliferation. By inhibiting testosterone production or action, hormonal therapy can help manage symptoms and slow down cancer progression.
**Why the Correct Answer is Testosterone:** Testosterone is the primary hormone involved in prostate cancer progression, as it stimulates the growth and proliferation of prostate cancer cells. By reducing testosterone levels, hormonal therapy can inhibit cancer growth and alleviate symptoms.
**Why the Correct Answer is Not Estrogen:** Estrogen antagonists are used in cases where prostate cancer has spread to the bone and causes bone pain due to estrogen receptors present in prostate cancer cells. Estrogen antagonists are not typically used for primary prostate cancer treatment.
**Why the Correct Answer is Not Gonadotropin Inhibiting Hormone (GnRH) Agonists:** GnRH agonists and antagonists are used to suppress testosterone production by blocking the GnRH stimulation of the pituitary gland, which in turn inhibits LH and FSH secretion. Testosterone suppression is achieved by inhibiting the production of LH and FSH, which stimulate testicular testosterone production.
**Why the Correct Answer is Not Gonadotropin Inhibiting Hormone (GnRH